UniQure, chasing Spark-level FIX activity, tweaks hemophilia B gene therapy ahead of 2018 pivotal trial – FierceBiotech
|
UniQure, chasing Spark-level FIX activity, tweaks hemophilia B gene therapy ahead of 2018 pivotal trial
FierceBiotech UniQure has modified its hemophilia B gene therapy to dial up factor IX (FIX) activity to the levels achieved by Spark Therapeutics’ rival product. The mid-development tweaks have the blessing of regulators, enabling uniQure to start a pivotal trial … |
|
FDA approves Gilead cancer gene therapy; price set at $373000
Reuters (Reuters) – U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc’s (GILD.O) Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. |
Slate Magazine |
Smallpox Could Again Be a Serious Threat
Slate Magazine SynBioBeta, which bills itself as the world’s premier forum for innovators and investors interested in synthetic biology, concluded its sixth annual conference in San Francisco earlier this month. Companies from across the country and from around the … |
Slate Magazine |
Smallpox Could Again Be a Serious Threat
Slate Magazine SynBioBeta, which bills itself as the world’s premier forum for innovators and investors interested in synthetic biology, concluded its sixth annual conference in San Francisco earlier this month. Companies from across the country and from around the … |